GLAXO.NS
Cash Flow
Glaxosmithkline Pharmaceuticals Ltd. · Healthcare
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-09-23 02:14
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹484.23 Cr. | ₹582.00 Cr. | ₹1,289.91 Cr. | ₹903.30 Cr. | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹807.85 Cr. | ₹8.72 Cr. | ₹-45.81 Cr. | ₹396.98 Cr. | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹-1,543.33 Cr. | ₹-561.49 Cr. | ₹-769.42 Cr. | ₹-737.08 Cr. | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹-251.25 Cr. | ₹29.23 Cr. | ₹474.68 Cr. | ₹563.20 Cr. | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹286.19 Cr. | ₹34.94 Cr. | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
| Dividends Paid | ₹1,525.50 Cr. | ₹541.57 Cr. | ₹749.38 Cr. | ₹713.97 Cr. | DividendsPaidClassifiedAsFinancingActivities |
Every figure above is the exact value of the named XBRL element from GLAXO.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).